$MRUS News
Last published 3mo ago
- 3mo agoLONAMRUSLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireOn Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL,
- 6mo agoMRUSApproval of Bizengri, Bla #761352FDA Approved DrugsApproval Date: 05/11/2026; Drug Name: Bizengri, Bla #761352; Active Ingredients: ZENOCUTUZUMAB-ZBCO; Company: Merus N.v.; Submission Status: Approval; Application Number: 761352
- 6mo agoLONAMRUSLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete
- 6mo agoLONAMRUSLeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.GlobeNewswireBOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs,
- 9mo agoAVBPSMMTMRUSMRK+9EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightPR NewswireDelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs,...
- 11mo agoONCYAIMAVBPMRUS+1Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR NewswireUSANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination...
- 11mo agoGMABMRUSGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodBusiness WireCompany Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of
- 11mo agoGMABMRUSGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodGlobeNewswireCompany Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolioTransaction anticipated to be accretive to Genmab's EBITDA by end of 2029
- 12mo agoMRUSHALOMerus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of PetosemtamabPR NewswireMerus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates...
- 1y agoMRUSMerus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated SafetyGlobeNewswire– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct.
- 1y agoMRUSMerus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswire- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14,
- 1y agoMRUSMerus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswire- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The
- 1y agoMRUSEQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transactionPR NewswireEQT Life Sciences, a leading European life sciences venture capital firm, is pleased to share that Genmab (CPH: GMAB) has entered into a definitive...
- 1y agoGMABMRUSGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelBusiness WireCompany Announcement
- 1y agoGMABMRUSGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelGlobeNewswireCompany Announcement
- 1y agoMRUSXNCRMerus N.V. vs Xencor, Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoMRUSXNCRMerus N.V. vs Xencor, Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoMRUSMerus to Present at the 2025 Wells Fargo Healthcare ConferenceGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates
- 1y agoMRUSMerus to Present at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates
- 1y agoMRUSMerus Announces Financial Results for the Second Quarter 2025 and Provides Business UpdateGlobeNewswire- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the
- 1y agoMRUSMerus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), an oncology company developing innovative, full-length multispecific
- 1y agoMRUSMerus N.V. Announces Pricing of Public Offering of Common SharesGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), an oncology company developing innovative, full-length multispecific
- 1y agoMRUSMerus N.V. Announces Proposed Public Offering of Common SharesGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), an oncology company developing innovative, full-length multispecific
- 1y agoMRUSMerus to Present at Upcoming Investor ConferencesGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates
- 1y agoMRUSMerus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCCGlobeNewswire- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The
- 1y agoMRUSMerus Announces the Journal Publication of Petosemtamab Mechanism of ActionGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), an oncology company developing innovative, full-length multispecific
- 1y agoMRUSMerus to Present at BofA Securities 2025 Health Care ConferenceGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and
- 1y agoMRUSMerus Announces Financial Results for the First Quarter 2025 and Provides Business UpdateGlobeNewswire- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash,
- 1y agoMRUSMerus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual MeetingGlobeNewswire- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set
- 1y agoMRUSMerus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates
- 1y agoMRUSMerus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business UpdateGlobeNewswire- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
- 1y agoMRUSMerus to Present at Upcoming Investor ConferencesGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug
- 1y agoMRUSPetosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinomaGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug
- 1y agoMRUSMerus to Present at Citi's 2025 Virtual Oncology Leadership SummitGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics®
- 1y agoMRUSNew England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive CancerGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length
- 1y agoBHVNMRUSMerus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsGlobeNewswireNEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE:BHVN) and Merus N.V. (NASDAQ:MRUS), today announced a research collaboration and license
- 1y agoMRUSMerus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics®
- 1y agoMRUSMerus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCCGlobeNewswirePetosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data
- 1y agoMRUSMerus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy StudyGlobeNewswireBIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and Partner
- 1y agoMRUSMerus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive CancerGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length
- 1y agoMRUSMerus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024GlobeNewswire– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set UTRECHT, The
- 2y agoMRUSMerus Receives FDA extension of PDUFA for zenocutuzumabGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length
- 2y agoMRUSMerus Announces Financial Results for the Third Quarter 2024 and Provides Business UpdateGlobeNewswirePhase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for
- 2y agoMRUSMerus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCCGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length
- 2y agoMRUSMerus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024GlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length
- 2y agoMRUSFoundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA PlatformBusiness WireFoundation Medicine, Inc. today announced a collaboration to develop Foundation Medicine's RNA platform as a companion diagnostic for Merus N.V.'s (NASDAQ:MRUS) bispecific antibody zenocutuzumab (Zeno) to treat patients
- 2y agoONCYHALOCADLMRUSBiotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival RatesPR NewswireUSA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns ...
- 2y agoMRUSMerus to Present at Canaccord Genuity's 44th Annual Growth ConferenceGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics®
- 2y agoMRUSMerus Announces Financial Results for the Second Quarter 2024 and Provides Business UpdateGlobeNewswire– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating
- 2y agoMRUSMerus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCCGlobeNewswireUTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length